Tri Locum Partners’s Sarepta Therapeutics SRPT Stock Holding History

Tri Locum Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-88,961	Closed	-$12.3M	–	76
2023 Q1	$12.3M	Sell	88,961 -30,734	-26%	-$3.99M	3.73%	9
2022 Q4	$15.5M	Buy	119,695 +24,250	+25%	+$2.81M	6.27%	3
2022 Q3	$10.6M	Buy	+95,445	New	+$9.62M	2.9%	15
2021 Q4	–	Sell	-135,055	Closed	-$12.5M	–	51
2021 Q3	$12.5M	Buy	+135,055	New	+$10.4M	4.96%	10

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tri Locum Partners's SRPT Position: Q2 2023 in Review

Tri Locum Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 88,961 shares — an estimated $12.3M sold.

Tri Locum Partners first reported a position in SRPT in Q3 2021 and held it in 4 quarters. The position peaked at $15.5M in Q4 2022. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

Tri Locum Partners reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
Tri Locum Partners sold 88,961 Sarepta Therapeutics shares in Q2 2023, an estimated $12.3M.
Tri Locum Partners first reported a position in Sarepta Therapeutics in Q3 2021 and held it in 4 quarters.
Tri Locum Partners's Sarepta Therapeutics position peaked at $15.5M in Q4 2022.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.